Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PANK1 | Q8TE04 | 1/20 | 0.43 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RGS12 | O14924 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4405756 | 0.88 | MAPT (0.52) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL4409427 | 0.86 | L3MBTL1 (0.51) | MAPTHTTPANK1PANK3ALDH1A1 | |
| SCHEMBL8219367 | 0.82 | HTT (0.53) | MAPTHTTPKMKDM4EALDH1A1 | |
| SCHEMBL4415982 | 0.78 | NPSR1 (0.38) | PKMKDM4EALDH1A1EGFRGAA | |
| SCHEMBL17755717 | 0.69 | MAPT (0.53) | MAPTHTTPKMKDM4EALDH1A1 | |
| SCHEMBL17755721 | 0.68 | MAPT (0.51) | MAPTHTTPKMKDM4EALDH1A1 | |
| SCHEMBL29160657 | 0.68 | NPC1 (0.53) | MAPTKDM4EALDH1A1KMT2APOLB | |
| SCHEMBL3342586 | 0.67 | L3MBTL1 (0.80) | MAPTHTTKDM4EALDH1A1EGFR | |
| Methyl Alcohol SCHEMBL4593446 | 0.67 | MAPT (0.93) | MAPTHTTALDH1A1KMT2ALMNA | |
| SCHEMBL4414249 | 0.67 | LMNA (0.52) | PTGDR2ALDH1A1KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2020408-A1 | Pyrrole substituted 2-indolinone protein kinase inhibitors | Sugen, Inc. (US) | 2009-02-04 | — | — | EP | disclosed |
| US-7189721-B2 | Bicyclic protein kinase inhibitors | SUGEN INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7119090-B2 | Pyrrole substituted 2-indolinone protein kinase inhibitors | SUGEN, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | SUGEN, INC. | 2004-06-03 | — | — | US | disclosed |
| US-6696448-B2 | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER, DIABETES, AUTOIMMUNE DISORDERS, HYPERPROLIFERATIVE DISORDERS SUCH AS RHEUMATOID ARTHRITIS AND INFLAMMATORY DISORDERS | SUGEN, INC. | 2004-02-24 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6683082-B2 | 3-HETERO-ARYLIDENE-2-INDOLINONE COMPOUNDS; ANTICANCER AGENTS | SUGEN, INC. | 2004-01-27 | — | — | US | disclosed |
| US-6579897-B2 | For therapy of cancer, arthritis, diabetic retinopathy, restinosis, hepatic cirrhosis, atherosclerosis, angiogenesis, glomerulonephritis, diabetic nephropathy, thrombic microangiopathy syndromes, transplant rejection | SUGEN, INC. | 2003-06-17 | — | — | US | disclosed |
| US-20020058661-A1 | Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors | TANG PENG CHO (US) | 2002-05-16 | — | — | US | disclosed |
| US-6350754-B2 | ANTICARCINOGENIC AGENTS | SUGEN, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20010056094-A1 | Anticarcinogenic agents | TANG PENG CHO (US) | 2001-12-27 | — | — | US | disclosed |
| US-6316429-B1 | ENZYME INHIBITORS MODULATE THE ACTIVITY OF PROTEIN KINASES AND THEREFORE ARE EXPECTED TO BE USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER. | SUGEN, INC. | 2001-11-13 | — | — | US | disclosed |
| US-6313158-B1 | THERAPY AND PROPHYLAXIS OF CANCER | SUGEN, INC. | 2001-11-06 | — | — | US | disclosed |
| EP-1082305-A4 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN INC (US) | 2001-09-26 | — | — | EP | disclosed |
| WO-2001037820-A2 | IONIZABLE INDOLINONE DERIVATIVES AND THEIR USE AS PTK LIGANDS | SUGEN, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1082305-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2001-03-14 | — | — | EP | disclosed |
| US-6051593-A | USEFUL IN THE PREVENTION AND TREATMENT OF PROTEIN TYROSINE KINASE RELATED CELLULAR DISORDERS SUCH AS CANCER | SUGEN, INC. (US) | 2000-04-18 | — | — | US | disclosed |
| WO-1999061422-A1 | PYRROLE SUBSTITUTED 2-INDOLINONE PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 1999-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010056094-A1 | Anticarcinogenic agents | GSTK1, CDC42BPG, GLS | MAPT 4728/4885HTT 3559/4885PKM 1867/4885 |
| US-20040106618-A1 | Bicyclic protein kinase inhibitors | MAP3K20, MAP4K3, MAP4K2 | MAPT 3296/4885HTT 3823/4885PKM 489/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | MAPT 4113/4885HTT 4537/4885PKM 477/4885 |
| US-20020058661-A1 | Bioavailability 3-heteroarylidenyl-2-indolinones active as protein tyrosine kinase inhibitors | TH, DSTYK, ERBB2 | MAPT 3037/4885HTT 1514/4885PKM 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.